Enfusion (ENFN)
(Delayed Data from NYSE)
$9.42 USD
0.00 (0.00%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $9.42 0.00 (0.00%) 7:06 PM ET
4-Sell of 5 4
F Value A Growth C Momentum C VGM
Balance Sheet
Fiscal Year End for Enfusion, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 36 | 63 | 64 | 14 | 0 |
Receivables | 28 | 26 | 18 | 12 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 6 | 8 | 7 | 3 | 0 |
Total Current Assets | 70 | 97 | 90 | 29 | 0 |
Net Property & Equipment | 18 | 16 | 13 | 9 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 7 | 4 | 3 | 1 | 0 |
Total Assets | 109 | 124 | 106 | 39 | 0 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 2 | 3 | 0 | 0 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 3 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 14 | 12 | 6 | 8 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 20 | 17 | 8 | 11 | 0 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 96 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 1 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 166 | 0 |
Total Liabilities | 31 | 20 | 9 | 273 | 0 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 227 | 244 | 227 | 0 | 0 |
Retained Earnings | -173 | -179 | -171 | 0 | 0 |
Other Equity | 23 | 38 | 42 | -234 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 77 | 103 | 97 | -234 | 0 |
Total Liabilities & Shareholder's Equity | 109 | 124 | 106 | 39 | 0 |
Total Common Equity | 77 | 103 | 97 | -234 | 0 |
Shares Outstanding | 127.50 | 114.00 | 113.00 | NA | NA |
Book Value Per Share | 0.61 | 0.91 | 0.86 | 0.00 | 0.00 |
Fiscal Year End for Enfusion, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 36 | 32 | 28 | 55 |
Receivables | NA | 28 | 25 | 25 | 24 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 6 | 6 | 7 | 8 |
Total Current Assets | NA | 70 | 62 | 60 | 87 |
Net Property & Equipment | NA | 18 | 18 | 18 | 17 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 7 | 6 | 5 | 5 |
Total Assets | NA | 109 | 102 | 94 | 121 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 2 | 1 | 1 | 1 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 14 | 11 | 8 | 7 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 20 | 16 | 14 | 14 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 31 | 28 | 22 | 22 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 227 | 225 | 224 | 240 |
Retained Earnings | NA | -173 | -174 | -175 | -176 |
Other Equity | NA | 23 | 22 | 24 | 35 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 77 | 73 | 72 | 99 |
Total Liabilities & Shareholder's Equity | NA | 109 | 102 | 94 | 121 |
Total Common Equity | 0 | 77 | 73 | 72 | 99 |
Shares Outstanding | 128.00 | 127.50 | 127.40 | 123.40 | 115.20 |
Book Value Per Share | 0.00 | 0.61 | 0.58 | 0.59 | 0.86 |